Lamouliatte H, Samoyeau R, De Mascarel A, Megraud F
Service des Maladies de l'Appareil Digestif, Hôpital Saint-André, Bordeaux, France.
Aliment Pharmacol Ther. 1999 Nov;13(11):1523-30. doi: 10.1046/j.1365-2036.1999.00646.x.
The necessity of increasing intragastric pH during eradication treatment in Helicobacter pylori infected patients is well established. However, the optimal dose of the proton pump inhibitors used in eradication regimen is still a subject of debate.
To compare the efficacy and tolerability of a double vs. a single daily dose of pantoprazole in a 7-day triple therapy in eradicating H. pylori.
In this regional, multicentre, comparative, randomized and double-blind study, H. pylori-positive patients with non-ulcer dyspepsia were treated for 7 days with clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. and either a double (2 x 40 mg, Group 2PCA) or a single (40 mg, Group 1PCA) daily dose of pantoprazole. H. pylori infection was assessed at entry and at the end (day 38) of the study by histology and culture, or in some cases by 13C-urea breath test.
From 203 patients recruited, 192 patients (96 in Group 2PCA and 96 in Group 1PCA) formed the intention-to-treat population. Twenty-six of them judged as major protocol violators were excluded from the per protocol analysis. H. pylori eradication rate was 75% in Group 2PCA and 56% in Group 1PCA in intention-to-treat analysis, and 80% in Group 2PCA and 59% in Group 1PCA in per protocol analysis (P < 0.05). The primary resistance to clarithromycin was 10.5%. The eradication rates for the clarithromycin susceptible strains were 86% for Group 2PCA and 71% for Group 1PCA in per protocol analysis (P < 0.05). Both regimens led to similar improvement of clinical symptoms and were equally well tolerated.
A double (2 x 40 mg) daily dose of pantoprazole in a 7-day triple therapy is more effective than a single (40 mg) dose of this drug in eradication of H. pylori.
幽门螺杆菌感染患者根除治疗期间提高胃内pH值的必要性已得到充分证实。然而,根除方案中使用的质子泵抑制剂的最佳剂量仍是一个有争议的话题。
比较泮托拉唑每日双倍剂量与单倍剂量在7天三联疗法中根除幽门螺杆菌的疗效和耐受性。
在这项区域性、多中心、比较、随机和双盲研究中,非溃疡性消化不良的幽门螺杆菌阳性患者接受7天治疗,服用克拉霉素500mg,每日2次,阿莫西林1000mg,每日2次,以及双倍剂量(2×40mg,第2PCA组)或单倍剂量(40mg,第1PCA组)的泮托拉唑。在研究开始时和结束时(第38天)通过组织学和培养评估幽门螺杆菌感染情况,在某些情况下通过13C-尿素呼气试验评估。
从招募的203例患者中,192例患者(第2PCA组96例,第1PCA组96例)构成意向性治疗人群。其中26例被判定为主要方案违反者被排除在符合方案分析之外。意向性治疗分析中,第2PCA组幽门螺杆菌根除率为75%,第1PCA组为56%;符合方案分析中,第2PCA组为80%,第1PCA组为59%(P<0.05)。对克拉霉素的原发性耐药率为10.5%。符合方案分析中,第2PCA组对克拉霉素敏感菌株的根除率为86%,第1PCA组为71%(P<0.05)。两种方案均使临床症状得到类似改善,耐受性相当。
在7天三联疗法中,泮托拉唑每日双倍剂量(2×40mg)在根除幽门螺杆菌方面比单倍剂量(40mg)更有效。